Cargando…
Brain metastases free survival differs between breast cancer subtypes
BACKGROUND: Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273356/ https://www.ncbi.nlm.nih.gov/pubmed/22233926 http://dx.doi.org/10.1038/bjc.2011.597 |
_version_ | 1782222924616302592 |
---|---|
author | Berghoff, A Bago-Horvath, Z De Vries, C Dubsky, P Pluschnig, U Rudas, M Rottenfusser, A Knauer, M Eiter, H Fitzal, F Dieckmann, K Mader, R M Gnant, M Zielinski, C C Steger, G G Preusser, M Bartsch, R |
author_facet | Berghoff, A Bago-Horvath, Z De Vries, C Dubsky, P Pluschnig, U Rudas, M Rottenfusser, A Knauer, M Eiter, H Fitzal, F Dieckmann, K Mader, R M Gnant, M Zielinski, C C Steger, G G Preusser, M Bartsch, R |
author_sort | Berghoff, A |
collection | PubMed |
description | BACKGROUND: Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated between 1996 until 2010. METHODS: Brain metastases free survival was measured as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of BM. HER-2 status was analysed by immunohistochemistry and reanalysed by fluorescent in situ hybridisation if a score of 2+ was gained. Oestrogen-receptor (ER) and progesterone-receptor (PgR) status was analysed by immunohistochemistry. Brain metastases free survival curves were estimated with the Kaplan–Meier method and compared with the log-rank test. RESULTS: Data of 213 patients (46 luminal/124 HER-2/43 triple-negative subtype) with BM from breast cancer were available for the analysis. Brain metastases free survival differed significantly between breast cancer subtypes. Median BMFS in triple-negative tumours was 14 months (95% CI: 11.34–16.66) compared with 18 months (95% CI: 14.46–21.54) in HER-2-positive tumours (P=0.001) and 34 months (95% CI: 23.71–44.29) in luminal tumours (P=0.001), respectively. In HER-2-positive patients, co-positivity for ER and HER-2 prolonged BMFS (26 vs 15 m; P=0.033); in luminal tumours, co-expression of ER and PgR was not significantly associated with BMFS. Brain metastases free survival in patients with lung metastases was significantly shorter (17 vs 21 months; P=0.014). CONCLUSION: Brain metastases free survival in triple-negative breast cancer, as well as in HER-2-positive/ER-negative, is significantly shorter compared with HER-2/ER co-positive or luminal tumours, mirroring the aggressiveness of these breast cancer subtypes. |
format | Online Article Text |
id | pubmed-3273356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32733562013-01-31 Brain metastases free survival differs between breast cancer subtypes Berghoff, A Bago-Horvath, Z De Vries, C Dubsky, P Pluschnig, U Rudas, M Rottenfusser, A Knauer, M Eiter, H Fitzal, F Dieckmann, K Mader, R M Gnant, M Zielinski, C C Steger, G G Preusser, M Bartsch, R Br J Cancer Clinical Studies BACKGROUND: Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated between 1996 until 2010. METHODS: Brain metastases free survival was measured as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of BM. HER-2 status was analysed by immunohistochemistry and reanalysed by fluorescent in situ hybridisation if a score of 2+ was gained. Oestrogen-receptor (ER) and progesterone-receptor (PgR) status was analysed by immunohistochemistry. Brain metastases free survival curves were estimated with the Kaplan–Meier method and compared with the log-rank test. RESULTS: Data of 213 patients (46 luminal/124 HER-2/43 triple-negative subtype) with BM from breast cancer were available for the analysis. Brain metastases free survival differed significantly between breast cancer subtypes. Median BMFS in triple-negative tumours was 14 months (95% CI: 11.34–16.66) compared with 18 months (95% CI: 14.46–21.54) in HER-2-positive tumours (P=0.001) and 34 months (95% CI: 23.71–44.29) in luminal tumours (P=0.001), respectively. In HER-2-positive patients, co-positivity for ER and HER-2 prolonged BMFS (26 vs 15 m; P=0.033); in luminal tumours, co-expression of ER and PgR was not significantly associated with BMFS. Brain metastases free survival in patients with lung metastases was significantly shorter (17 vs 21 months; P=0.014). CONCLUSION: Brain metastases free survival in triple-negative breast cancer, as well as in HER-2-positive/ER-negative, is significantly shorter compared with HER-2/ER co-positive or luminal tumours, mirroring the aggressiveness of these breast cancer subtypes. Nature Publishing Group 2012-01-31 2012-01-10 /pmc/articles/PMC3273356/ /pubmed/22233926 http://dx.doi.org/10.1038/bjc.2011.597 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Studies Berghoff, A Bago-Horvath, Z De Vries, C Dubsky, P Pluschnig, U Rudas, M Rottenfusser, A Knauer, M Eiter, H Fitzal, F Dieckmann, K Mader, R M Gnant, M Zielinski, C C Steger, G G Preusser, M Bartsch, R Brain metastases free survival differs between breast cancer subtypes |
title | Brain metastases free survival differs between breast cancer subtypes |
title_full | Brain metastases free survival differs between breast cancer subtypes |
title_fullStr | Brain metastases free survival differs between breast cancer subtypes |
title_full_unstemmed | Brain metastases free survival differs between breast cancer subtypes |
title_short | Brain metastases free survival differs between breast cancer subtypes |
title_sort | brain metastases free survival differs between breast cancer subtypes |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273356/ https://www.ncbi.nlm.nih.gov/pubmed/22233926 http://dx.doi.org/10.1038/bjc.2011.597 |
work_keys_str_mv | AT berghoffa brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT bagohorvathz brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT devriesc brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT dubskyp brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT pluschnigu brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT rudasm brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT rottenfussera brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT knauerm brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT eiterh brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT fitzalf brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT dieckmannk brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT maderrm brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT gnantm brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT zielinskicc brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT stegergg brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT preusserm brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes AT bartschr brainmetastasesfreesurvivaldiffersbetweenbreastcancersubtypes |